Outcome after heart-lung or lung transplantation in patients with Eisenmenger syndrome

Cristel S. Hjortshøj, Thomas Gilljam, Göran Dellgren, Markku O. Pentikäinen, Thomas Möller, Annette Schophuus Jensen, Maila Turanlahti, Ulf Thilén, Finn Gustafsson, Lars Søndergaard

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: The optimal timing for transplantation is unclear in patients with Eisenmenger syndrome (ES). We investigated post-transplantation survival and transplantation-specific morbidity after heart-lung transplantation (HLTx) or lung transplantation (LTx) in a cohort of Nordic patients with ES to aid decision-making for scheduling transplantation. Methods: We performed a retrospective, descriptive, population-based study of patients with ES who underwent transplantation from 1985 to 2012. Results: Among 714 patients with ES in the Nordic region, 63 (9%) underwent transplantation. The median age at transplantation was 31.9 (IQR 21.1-42.3) years. Within 30 days after transplantation, seven patients (11%) died. The median survival was 12.0 (95% CI 7.6 to 16.4) years and the overall 1-year, 5-year, 10-year and 15-year survival rates were 84.1%, 69.7%, 55.8% and 40.6%, respectively. For patients alive 1 year post-transplantation, the median conditional survival was 14.8 years (95% CI 8.0 to 21.8), with 5-year, 10-year and 15-year survival rates of 83.3%, 67.2% and 50.0%, respectively. There was no difference in median survival after HLTx (n=57) and LTx (n=6) (14.9 vs 10.6 years, p=0.718). Median cardiac allograft vasculopathy, bronchiolitis obliterans syndrome and dialysis/kidney transplantation-free survival rates were 11.2 (95% CI 7.8 to 14.6), 6.9 (95% CI 2.6 to 11.1) and 11.2 (95% CI 8.8 to 13.7) years, respectively. The leading causes of death after the perioperative period were infection (36.7%), bronchiolitis obliterans syndrome (23.3%) and heart failure (13.3%). Conclusions: This study shows that satisfactory post-transplantation survival, comparable with contemporary HTx and LTx data, without severe comorbidities such as cardiac allograft vasculopathy, bronchiolitis obliterans syndrome and dialysis, is achievable in patients with ES, with a conditional survival of nearly 15 years.

Original languageEnglish
Pages (from-to)127-132
JournalHeart
Volume106
Issue number2
Early online date2019
DOIs
Publication statusPublished - 2020

Subject classification (UKÄ)

  • Surgery

Free keywords

  • Eisenmenger syndrome
  • heart-lung transplantation
  • lung transplantation

Fingerprint

Dive into the research topics of 'Outcome after heart-lung or lung transplantation in patients with Eisenmenger syndrome'. Together they form a unique fingerprint.

Cite this